Voyager Therapeutics (VYGR) Competitors $4.25 +0.04 (+0.95%) Closing price 03:59 PM EasternExtended Trading$4.24 -0.01 (-0.24%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. UPB, RAPP, SYRE, URGN, ABUS, PRAX, IMNM, TSHA, IOVA, and PHATShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Upstream Bio (UPB), Rapport Therapeutics (RAPP), Spyre Therapeutics (SYRE), Urogen Pharma (URGN), Arbutus Biopharma (ABUS), Praxis Precision Medicines (PRAX), Immunome (IMNM), Taysha Gene Therapies (TSHA), Iovance Biotherapeutics (IOVA), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Its Competitors Upstream Bio Rapport Therapeutics Spyre Therapeutics Urogen Pharma Arbutus Biopharma Praxis Precision Medicines Immunome Taysha Gene Therapies Iovance Biotherapeutics Phathom Pharmaceuticals Voyager Therapeutics (NASDAQ:VYGR) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Is VYGR or UPB more profitable? Voyager Therapeutics has a net margin of -253.49% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Voyager Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-253.49% -37.65% -28.89% Upstream Bio -3,836.58%-35.90%-26.26% Do analysts rate VYGR or UPB? Voyager Therapeutics presently has a consensus target price of $13.25, suggesting a potential upside of 211.33%. Upstream Bio has a consensus target price of $56.50, suggesting a potential upside of 220.02%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, VYGR or UPB? Upstream Bio has lower revenue, but higher earnings than Voyager Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$42.58M5.54-$65M-$1.85-2.30Upstream Bio$2.37M401.60-$62.81MN/AN/A Does the media prefer VYGR or UPB? In the previous week, Voyager Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Voyager Therapeutics and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.94 beat Voyager Therapeutics' score of 0.83 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of VYGR or UPB? 48.0% of Voyager Therapeutics shares are owned by institutional investors. 6.4% of Voyager Therapeutics shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryVoyager Therapeutics and Upstream Bio tied by winning 7 of the 14 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$236.58M$3.10B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-2.3121.3675.8126.51Price / Sales5.54386.19492.95166.26Price / CashN/A44.4425.8129.90Price / Book0.789.6112.836.31Net Income-$65M-$53.28M$3.28B$270.12M7 Day Performance6.11%0.44%0.24%2.04%1 Month Performance14.08%4.68%4.59%6.25%1 Year Performance-31.70%10.08%68.69%25.50% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics3.8569 of 5 stars$4.25+1.0%$13.25+211.7%-32.6%$235.74M$42.58M-2.30100News CoveragePositive NewsAnalyst ForecastUPBUpstream Bio1.5385 of 5 stars$16.79-4.4%$56.50+236.5%N/A$905.13M$2.72M0.0038RAPPRapport Therapeutics3.0965 of 5 stars$24.73+4.1%$31.00+25.4%+30.2%$902.65MN/A-9.89N/AAnalyst UpgradeGap UpHigh Trading VolumeSYRESpyre Therapeutics2.4449 of 5 stars$14.84-5.2%$53.40+259.8%-49.5%$896.34M$890K-4.3673News CoverageAnalyst ForecastURGNUrogen Pharma4.0582 of 5 stars$18.06-3.9%$32.00+77.2%+37.7%$869.30M$91.87M-5.44200Analyst UpgradeABUSArbutus Biopharma1.8783 of 5 stars$4.53+1.6%$5.00+10.4%+1.3%$868.40M$6.17M-15.6290PRAXPraxis Precision Medicines2.305 of 5 stars$40.45+7.3%$85.88+112.3%-32.4%$851.47M$8.55M-3.29110Positive NewsIMNMImmunome2.3597 of 5 stars$9.48+2.9%$22.89+141.4%-40.6%$825.14M$9.04M-3.0840Positive NewsTSHATaysha Gene Therapies2.46 of 5 stars$3.02-1.6%$8.29+174.4%+31.9%$823.86M$8.33M-8.88180Positive NewsIOVAIovance Biotherapeutics4.1696 of 5 stars$2.27flat$11.90+424.2%-78.0%$821.41M$241.53M-1.85500PHATPhathom Pharmaceuticals2.3724 of 5 stars$11.48-3.0%$17.50+52.4%-37.3%$814.39M$55.25M-2.43110News Coverage Related Companies and Tools Related Companies Upstream Bio Alternatives Rapport Therapeutics Alternatives Spyre Therapeutics Alternatives Urogen Pharma Alternatives Arbutus Biopharma Alternatives Praxis Precision Medicines Alternatives Immunome Alternatives Taysha Gene Therapies Alternatives Iovance Biotherapeutics Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYGR Stock Alerts